Relating to warning labels for opioid prescription drugs.
Relating to warning labels for opioid prescription drugs.
Relating to distinctive packaging for opioid prescription drugs.
Relating to an acknowledgment on receipt of an opioid prescription drug.
Relating to a pilot program for the safe disposal of prescription drugs, including controlled substance prescription drugs.
Relating to health benefit plan coverage of prescription drugs for serious mental illnesses and opioid and substance use disorders.
Relating to promoting, prescribing, administering, or dispensing prescription drugs for off-label use.
Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.
Relating to the prescriptive authority of certain psychologists; authorizing a fee.
Relating to the authority of pharmacists to order and furnish certain prescription drugs.